Afuco™ Anti-IGHE ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-007)

Customer Review

There are currently no Customer reviews or questions for AFC-TAB-007. Click the button above to contact us or submit your feedback about this product.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Omalizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Omalizumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "Omalizumab"

Anti-Human IGHE Recombinant Antibody (Omalizumab)

Recombinant monoclonal antibody to Human IgE. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, omalizumab does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells. IgE is commonly involved in type I hypersensitivity, which manifests the most prevalent allergic diseases. It has been estimated that as high as 20 to 40% of the populations who live a western lifestyle in economically advanced countries are affected by allergy and seek medical help. In the U.S., 8% of adults and 10% of children have asthma. While allergy occurs more frequently in individuals with higher serum IgE levels, such a correlation is only statistical and not absolute. Some allergic individuals have very low serum IgE, and some people with very high IgE have no allergic problems.

DrugMonitor™ Anti-Omalizumab Antibody (VS-1224-YC841)

Omalizumab is a monoclonal antibody targeting immunoglobulin E (IgE), and it is prescribed for asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergies. The DrugMonitor™ Anti-Omalizumab Antibody (VS-1224-YC841) is an anti-drug antibody (ADA) against Omalizumab. This drug-based antibody is raised in mice immunized with the Omalizumab. The anti-Omalizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Omalizumab in samples.

See other products for "IGHE"

Select a product category from the dropdown menu below to view related products.

Single Domain Antibodies Humanized Antibodies Immunotoxins Human Antibodies IgG Antibodies ScFv Antibodies Fab Antibodies ADCC Enhanced Antibodies ScFv-Fc Chimeras Extracellular Vesicle Antibodies IHC Kits & Antibodies Biparatopic Antibodies